Buy Stocks Easy | About Us

January 29, 2022

QURE

Buy uniQure N.V. Stock (symbol: QURE) Easy Online

Company Name: uniQure N.V.

Symbol: QURE

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2014

QURE Current Share Price

Today's QURE ( uniQure N.V. ) opening price: $

Yesterday's QURE ( uniQure N.V. ) closing price: $

uniQure N.V. Stock ( symbol: QURE ) Price Chart since IPO (2014):

12 Months uniQure N.V. Stock ( symbol: QURE ) Price Chart

Popular Questions about uniQure N.V. Public Stock ( QURE )

A: uniQure N.V. stock symbol (also called stock or share ticker) is QURE

A: uniQure N.V. IPO (Initial Public Offering) took place on 2014

A: uniQure N.V.'s stock (QURE symbol) price at ther IPO (initial Public Offering) was $

Q: Is QURE stock worth buying at the moment?

A: If you were looking for a long-term investment portfolio and had bought the 'uniQure N.V. stock (symbol: QURE) at the beginning of 2019, at the opening share price of $34.2500, with a minimum of $200, by now your shares would be worth $1366 and your profit would be $1166 - SHOW ONLY IF PROFIT.

Buy uniQure N.V. Stock Easy Online

uniQure N.V. Stock Ticker Price Chart since IPO:

uniQure N.V. Stock Price Yesterday

uniQure N.V. Stock Price – Last Week

uniQure N.V. Stock Price – Last Month

uniQure N.V. Stock Value Chart – 12 Months

Rate this post

Latest Stock News:

https://seekingalpha.com/article/4314536-5-best-mid-cap-biotech-acquisition-targets

5 Best Mid-Cap Biotech Acquisition Targets

5 Best Mid-Cap Biotech Acquisition Targets

https://www.fool.com/investing/2019/12/23/3-stocks-that-could-be-the-next-biotech-buyouts.aspx

3 Stocks That Could Be the Next Biotech Buyouts

Here are the biotechs most likely to receive juicy buyout offers in...

https://www.fool.com/investing/2019/12/19/the-top-biotech-stocks-to-watch-following-ash-2019.aspx

The Top Biotech Stocks to Watch Following ASH 2019

The potential to reshape treatment of blood cancer and disorders co...

http://www.globenewswire.com/news-release/2019/12/19/1962704/0/en/uniQure-Announces-Publication-of-Preclinical-Data-for-AMT-130-in-Huntington-s-Disease-Supporting-Non-Selective-HTT-Lowering-Approach.html

uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington’s Disease Supporting Non-Selective HTT-Lowering Approach

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 19, 2019 (G...

http://www.zacks.com/stock/news/674823/5-biotech-stocks-that-have-more-than-doubled-this-year

5 Biotech Stocks That Have More Than Doubled This Year

The biotech sector has had a good run in 2019 on the back of ongoin...

http://www.zacks.com/stock/news/674645/will-uniqure-continue-to-surge-higher

Will uniQure Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor i...

http://www.zacks.com/stock/news/673135/5-biotech-stocks-set-for-continued-rally-in-2020

5 Biotech Stocks Set for Continued Rally in 2020

The advance in gene therapy and RNA interference has boosted the bi...

http://www.globenewswire.com/news-release/2019/12/08/1957588/0/en/uniQure-Announces-One-Year-Follow-Up-Data-from-the-Phase-IIb-Study-of-Etranacogene-Dezaparvovec-and-Long-Term-Follow-Up-Data-for-AMT-060-in-Patients-with-Hemophilia-B.html

uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B

~ Sustained FIX Activity at Therapeutic Levels1 Up to 50% of Normal...

http://www.zacks.com/stock/news/655819/4-solid-gene-therapy-buyout-bets-post-audentes-astellas-deal

4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal

Gene therapy continues to draw attention with the recent spate of d...

All right reserved Buy Stocks Easy , 2019.